Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting
Background Health records can be used to measure medicine use and health outcomes. The public subsidy of lenalidomide in Australia was based on two phase III trials showing improved survival. Objective To use hospital pharmacy information management systems to determine survival outcomes for lenalidomide as a second line treatment in relapsed or refractory multiple myeloma (RRMM) patients. Setting Five public hospitals in Queensland, Australia. Method We extracted data on medicine use and survival for RRMM patients planned to start lenalidomide from pharmacy management and pathology databases. Descriptive statistical analyses (Kaplan–Meier curves) were used to calculate overall survival. Main outcome measure Overall survival. Results There were 136 patients who received at least one lenalidomide dose and 2234 cycles were ordered. The median age was 69 years and 54% were male. Two lenalidomide containing protocols were considered: 90% of patients had lenalidomide plus dexamethasone; 18% had lenalidomide plus dexamethasone with cyclophosphamide. The median starting lenalidomide dose was 20 mg (range 4.3–25 mg) on days 1–21 of a 28-day cycle. Median time on treatment 9.4 months (range 0.5–71.7 months). Median overall survival was 45.4 months (range 12.0–70.5 months). Conclusion The median survival in our study compared favourably to clinical trials. Patients and clinicians can be reassured that outcomes in this clinical setting are as good as those observed in trials.
KeywordsAustralia Lenalidomide Multiple myeloma Pharmacy information system Refractory Relapsed Survival
The authors wish to thank Dr Joshua Richmond (Toowoomba Health Service), Dr Jeremy Wellwood (Gold Coast University Hospital), and Dr Kathryn Jackson (Nambour General Hospital) for their collaboration. We wish to thank the five Queensland public hospitals sites that provided data (Princess Alexandra Hospital, Toowoomba Health Service, Gold Coast University Hospital, Nambour General Hospital and Gympie Health Service); as well as the staff who entered the information into the databases at the Queensland Health sites. We thank the patients whose medical information were made available for this study. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. It was funded from existing salaries.
Conflicts of interest
PM is a member of the Myeloma Advisory Board of Celgene Australia. All other authors declare that the research was conducted in the absence of any commercial or financial interests.
- 2.Australian Institute of Health and Welfare & Australasian Association of Cancer Registries. Cancer in Australia: an overview, vol. 74., Cancer seriesCanberra: Australian Institute of Health and Welfare; 2012.Google Scholar
- 7.Australian Government Department of Health—Pharmaceutical Benefits Advisory Committee. Public summary document: lenalidomide (November 2008). http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2008-11/pbac-psd-lenalidomide-nov08. Accessed 3 Feb 2017.
- 10.Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008;112(12):4445–51.CrossRefPubMedGoogle Scholar
- 11.Australian Institute of Health and Welfare. What is chronic kidney disease?. Canberra: Australian Institute of Health and Welfare; 2015.Google Scholar
- 12.Therapeutic Guidelines Limited. Antibiotic eTG: renal impairment and antimicrobial dosing (Appendix 2.6). 2016 https://tgldcdp.tg.org.au/topicTeaser?guidelinePage=Antibiotic&etgAccess=true. Accessed 03 Feb 2017.
- 13.Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587–600.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd; 2017. https://shop.amh.net.au/faq/58#t58n14.
- 15.Abd ElHafeez S, Torino C, D’Arrigo G, Bolignano D, Provenzano F, Mattace-Raso F, et al. An overview on standard statistical methods for assessing exposure-outcome link in survival analysis (Part II): the Kaplan–Meier analysis and the Cox regression method. Aging Clin Exp Res. 2012;24(3):203–6.CrossRefPubMedGoogle Scholar
- 16.Australian Government Department of Health. Pharmaceutical benefits scheme (PBS). 2016 www.pbs.gov.au. Accessed 3 Feb 2017.
- 17.Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol. 2009;82(6):426–32.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Cancer Institute New South Wales. Multiple myeloma: chemotherapy protocols. 2015 https://www.eviq.org.au/Login.aspx?ReturnUrl=%2fCategory%2ftabid%2f65%2fcategoryid%2f319%2fDefault.aspx. Accessed 3 Feb 2017.